Skyrizi is used to treat autoimmune and inflammatory conditions like Crohn’s disease and plaque psoriasis. It is administered via intravenous injection by a healthcare professional or subcutaneous ...

Zepbound is a prescription injectable medication that’s used for weight loss. You or a caregiver can administer it as a subcutaneous injection into your stomach or thigh. A caregiver can also ...

Ozempic (semaglutide) is injected once weekly under the skin of your abdomen, upper arm, or thigh. Your doctor will show you how to do this before your first dose. To prevent skin issues, rotate your ...

The US Food and Drug Administration (FDA) has approved the biologics license application for a subcutaneous formulation of lecanemab (Leqembi Iqlik) for weekly maintenance dosing to treat Alzheimer’s ...

Please provide your email address to receive an email when new articles are posted on . Opdivo was previously only available intravenously. The approval comes after CHECKMATE-67T study results. Opdivo ...

Please provide your email address to receive an email when new articles are posted on . Genentech announced it received FDA approval for Ocrevus Zunovo to treat patients with relapsing and primary ...

Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

Injection site reactions are the most common side effect of Emgality. The most frequent injection site reaction is pain. But there are steps you can take to help prevent or reduce pain from Emgality ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III OCARINA II trial evaluating Ocrevus® (ocrelizumab) ...

argenx SE (NASDAQ:ARGX) said on Friday that it has received approval from the European Commission for its IgG Fc-antibody fragment, Vyvgart, at a 1000 mg dose, administered through a subcutaneous ...

Health Canada approves Pr AJOVY® (fremanezumab solution for subcutaneous injection) for the prevention of episodic migraine (fewer than 15 migraine days per month) in pediatric patients aged 6 to 17 ...